Topical Application of a Formulation Containing Pea Proteins and Xyloglucan in Adult Patients with Atopic Dermatitis: A Double-blind, Parallel, Randomized, Placebo-controlled, Multicenter Study.
ADSI
Atopic dermatitis
POEM
pea proteins
xyloglucan
Journal
The Journal of clinical and aesthetic dermatology
ISSN: 1941-2789
Titre abrégé: J Clin Aesthet Dermatol
Pays: United States
ID NLM: 101518173
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
medline:
10
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
ppublish
Résumé
Atopic dermatitis (AD) management requires long-term use of drugs that come with side effects. Compounds such as xyloglucan (XG) and pea proteins (PP) are emerging alternatives to corticosteroids that have shown to restore skin barrier function in preclinical studies. This double-blind, parallel, randomized, placebo-controlled clinical trial investigated the efficacy and safety of XG and PP, in adult AD patients. Fourty-two patients with AD were randomly assigned 1:1 to receive a XG+PP treatment or the vehicle without XG+PP twice/day for 14 consecutive days for assessment at baseline, Day 8 and Day 15; follow-up visit was 14 days after the end of treatment (Day 28). Efficacy was evaluated using the Scoring Atopic Dermatitis (SCORAD) index, AD severity index (ADSI) score and patient-oriented eczema measure (POEM). Safety and tolerability were monitored as the occurrence of Adverse Events (AEs). At baseline, both groups exclusively included moderate/severe AD cases. At Day 8, six patients treated with XG+PP displayed complete resolution of AD, while 15 patients had mild AD. At Day 28, 16 patients no longer had eczema, whereas five patients displayed mild AD. Notably, 21 patients in the vehicle group still displayed moderate/severe AD. XG and PP promote rapid and long-lasting relief, supporting its use as a safe alternative to mainstay corticosteroid treatments for AD management. The study protocol has been registered in the ISRCTN registry (TN66879853).
Types de publication
Journal Article
Langues
eng
Pagination
35-41Informations de copyright
Copyright © 2023. Matrix Medical Communications. All rights reserved.
Déclaration de conflit d'intérêts
DISCLOSURES: All authors report no conflicts of interest relevant to the content of this article.
Références
Clin Dermatol. 2018 Sep - Oct;36(5):606-615
pubmed: 30217273
Eur J Nutr. 2012 Feb;51(1):29-37
pubmed: 21442413
Semin Cutan Med Surg. 2017 Sep;36(3):100-103
pubmed: 28895955
Nature. 2018 Jan 24;553(7689):427-436
pubmed: 29364286
Contact Dermatitis. 1984 Jul;11(1):51
pubmed: 6744846
United European Gastroenterol J. 2019 Oct;7(8):1093-1101
pubmed: 31662866
J Drugs Dermatol. 2012 Oct;11(10):1174-8
pubmed: 23134982
Dermatol Ther. 2020 Nov;33(6):e14519
pubmed: 33169921
Skin Pharmacol Physiol. 2020;33(4):231-236
pubmed: 32846412
Arch Dermatol. 1980 Sep;116(9):1064-5
pubmed: 7416761
JAMA Pediatr. 2020 Jan 1;174(1):29-37
pubmed: 31764962
Am J Clin Dermatol. 2020 Sep;21(Suppl 1):44-50
pubmed: 32910440
Int J Mol Sci. 2020 Apr 20;21(8):
pubmed: 32326002
Am J Clin Dermatol. 2019 Dec;20(6):771-779
pubmed: 31140066
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1904-1926
pubmed: 36056736
Biomed Pharmacother. 2017 Sep;93:596-608
pubmed: 28686974
J Invest Dermatol. 2016 Jan;136(1):127-35
pubmed: 26763432
J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682
pubmed: 29676534
J Am Acad Dermatol. 2014 Aug;71(2):327-49
pubmed: 24813298
Patient Prefer Adherence. 2021 Aug 13;15:1763-1774
pubmed: 34413634
Regen Biomater. 2021 Aug 11;8(5):rbab040
pubmed: 34386265
CMAJ. 1988 Feb 15;138(4):336-8
pubmed: 2962713
Br J Nutr. 2012 Aug;108 Suppl 1:S3-10
pubmed: 22916813
Br J Dermatol. 2017 Oct;177(4):e125-e127
pubmed: 28244066
J Eur Acad Dermatol Venereol. 2005 May;19(3):326-31
pubmed: 15857459
Indian J Dermatol. 2014 Sep;59(5):460-4
pubmed: 25284850
Adv Exp Med Biol. 2017;1027:11-19
pubmed: 29063427
J Pharmacopuncture. 2020 Sep 30;23(3):173-178
pubmed: 33072415
Contact Dermatitis. 1982 May;8(3):164-7
pubmed: 7094571
J Am Acad Dermatol. 2014 Dec;71(6):1218-33
pubmed: 25264237
Allergy. 2021 Apr;76(4):1053-1076
pubmed: 33074565
Int J Mol Sci. 2020 May 19;21(10):
pubmed: 32438777
J Food Biochem. 2020 Apr;44(4):e13157
pubmed: 32020651
Therap Adv Gastroenterol. 2021 May 30;14:17562848211020570
pubmed: 34104216
Curr Probl Dermatol. 2016;49:8-26
pubmed: 26844894
J Am Acad Dermatol. 2014 Jul;71(1):116-32
pubmed: 24813302
Allergol Int. 2019 Jul;68(3):309-315
pubmed: 30878567
Nat Rev Dis Primers. 2018 Jun 21;4(1):1
pubmed: 29930242
Compr Rev Food Sci Food Saf. 2020 Jul;19(4):1835-1876
pubmed: 33337084
Trends Microbiol. 2018 Jun;26(6):484-497
pubmed: 29233606
Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):52
pubmed: 30275844
Clin Cosmet Investig Dermatol. 2022 Dec 14;15:2705-2719
pubmed: 36545500
Nat Genet. 2006 Apr;38(4):441-6
pubmed: 16550169
Vestn Dermatol Venerol. 1977 Dec;(12):44-5
pubmed: 607684
J Dermatol Sci. 2020 Jan;97(1):2-8
pubmed: 31866207
Iran J Immunol. 2019 Jun;16(2):97-107
pubmed: 31182684
Biomol Ther (Seoul). 2013 Jul 30;21(4):251-7
pubmed: 24244808